Soluble urokinase plasminogen activator receptor (suPAR) is a potential biomarker of stage III-IV, grade C periodontitis through the impact of post-radiotherapy on head and neck cancer patients

MLA

Ahmed A. Al-Kubaisi, et al. “Soluble Urokinase Plasminogen Activator Receptor (SuPAR) Is a Potential Biomarker of Stage III-IV, Grade C Periodontitis through the Impact of Post-Radiotherapy on Head and Neck Cancer Patients.” BMC Oral Health, vol. 24, no. 1, Sept. 2024, pp. 1–9. EBSCOhost, https://doi.org/10.1186/s12903-024-04801-w.

APA

Ahmed A. Al-Kubaisi, Maysam Abdulrahman Ghazi, Nisreen Salah Majeed, Ekram R. Aldelaimi, & Hamid H. Enezei. (2024). Soluble urokinase plasminogen activator receptor (suPAR) is a potential biomarker of stage III-IV, grade C periodontitis through the impact of post-radiotherapy on head and neck cancer patients. BMC Oral Health, 24(1), 1–9. https://doi.org/10.1186/s12903-024-04801-w

Chicago

Ahmed A. Al-Kubaisi, Maysam Abdulrahman Ghazi, Nisreen Salah Majeed, Ekram R. Aldelaimi, and Hamid H. Enezei. 2024. “Soluble Urokinase Plasminogen Activator Receptor (SuPAR) Is a Potential Biomarker of Stage III-IV, Grade C Periodontitis through the Impact of Post-Radiotherapy on Head and Neck Cancer Patients.” BMC Oral Health 24 (1): 1–9. doi:10.1186/s12903-024-04801-w.